Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia,JAMA Oncology

当前位置： X-MOL 学术 › JAMA Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
JAMA Oncology ( IF 28.4 ) Pub Date : 2024-04-18 , DOI: 10.1001/jamaoncol.2024.0473
Laurent Phely ₁ , Luca Hensen ₁ , Christoph Faul ₁ , Christer Alexander Ruff ₂ , Dina Schneider ₃ , Wolfgang Andreas Bethge ₁ , Claudia Lengerke ₁

Affiliation

This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.

中文翻译：